Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms

Area of Science:

• Oncology
• Immunology
• Bone Metastasis Research

Background:

• Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by enhancing T cell responses.
• However, ICIs are less effective in patients with bone metastases, leading to poorer outcomes.
• Adverse events like bone loss and fractures are associated with ICI treatment.

Purpose of the Study:

• To review current clinical and preclinical findings on immune checkpoint blockade in bone metastases.
• To highlight the limited efficacy and adverse effects of ICIs in this setting.
• To emphasize the need for further research into the bone-tumor microenvironment and immune cell interactions.

Main Methods:

• Review of clinical studies on ICI efficacy in bone metastases.
• Analysis of preclinical research on immune cell roles in bone metastasis.
• Synthesis of current literature on ICIs and the bone-tumor microenvironment.

Main Results:

• ICIs demonstrate reduced effectiveness in patients with bone metastases compared to other metastatic sites.
• Immune-related adverse events, including skeletal toxicities, are a concern with ICI therapy.
• Existing research suggests CD8+ T cells and myeloid cells influence bone homeostasis in metastatic disease.

Conclusions:

• The efficacy of ICIs is significantly diminished in the context of bone metastases.
• Understanding the complex interplay between immune cells and the bone microenvironment is crucial for improving ICI therapy.
• Further investigation is warranted to optimize immune-based strategies for treating bone metastases and mitigating associated toxicities.